Table 1 Demographic and clinical characteristics of patients diagnosed with gastric cancer.

From: Soluble HLA-G (sHLA-G) measurement might be useful as an early diagnostic biomarker and screening test for gastric cancer

Characteristic

N = 173

sHLA-G†

p-value

Gender, n (%)

 Male

119 (68.8)

13.8 [13.7]

0.026

 Female

54 (31.2)

6.44 [12.5]

 

Age at diagnosis (years)

 Mean ± SD

59.3 ± 12.9

  

Age group, n (%)

  ≤ 60 years

87 (50.3)

6.56 [12.6]

0.168

  > 60 years

86 (49.7)

9.36 [15.9]

 

Type of pathology§, n (%)

 Intestinal adenocarcinoma

101(58.4)

6.82 [13.7]

0.419

 Signet ring cell adenocarcinoma

45 (26.0)

8.04 [15.0]

 

 Other

27 (15.6)

12.5 [13.6]

 

Differentiation degree§, n (%)

 Well-differentiated

15 (8.70)

9.68 [10.6]

0.607

 Moderately differentiated

54 (31.2)

6.40 [17.3]

 

 Poorly differentiated

69 (39.9)

7.20 [11.0]

 

 No data

35 (20.2)

12.5 [12.8]

 

Tumor location§, n (%)

 Pyloric Antrum

49 (28.3)

8.91 [17.4]

0.227

 Cardias

41 (23.7)

6.36 [11.2]

 

 Body

73 (42.2)

9.33 [14.4]

 

 No data

10 (5.80)

13.2 [7.72]

 

Tumor stage§, n (%)

 In situ

1 (0.60)

127**

 

 I

14 (8.10)

3.35 [6.13]

0.082

 II

29 (16.8)

7.85 [16.7]

 

 III

47 (27.2)

6.89 [13.5]

 

 IV

51 (29.4)

11.2 [13.2]

 

 No data

31 (17.9)

12.0 [12.4]

 

Relapse, n (%)

 Yes

53 (30.6)

6.90 [14.2]

0.876

 No

120 (69.4)

9.06 [14.2]

 

Vital state, n (%)

 Dead

75 (43.4)

9.33 [13.9]

0.361

 Alive

98 (56.6)

8.18 [13.8]

 
  1. SD Standard deviation.
  2. Expression level in median [interquartile range].
  3. Wilcoxon signed rank testc.
  4. §Kruskal–Wallis test.
  5. **Only one patient presented stage in situ.